|Bid||79.77 x 900|
|Ask||80.34 x 1000|
|Day's Range||78.34 - 80.40|
|52 Week Range||57.17 - 89.74|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||22.16|
|Earnings Date||Apr 26, 2023 - May 01, 2023|
|Forward Dividend & Yield||3.00 (3.78%)|
|Ex-Dividend Date||Mar 14, 2023|
|1y Target Est||88.96|
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.